Related references
Note: Only part of the references are listed.The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
Christine Galustian et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy
Joseph A. Blansfield et al.
CLINICAL CANCER RESEARCH (2008)
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Lei Wu et al.
CLINICAL CANCER RESEARCH (2008)
Lenalidomide for the treatment of B-cell malignancies
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The role of the EGFR signaling in tumor microenvironment
Antonella De Luca et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma
David P. Mangiameli et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors
S. Kalmadi et al.
INVESTIGATIONAL NEW DRUGS (2007)
Thalidomide analogues as anticancer drugs
Jeanny B. Aragon-Ching et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2007)
The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes
Magda Melchert et al.
CURRENT OPINION IN HEMATOLOGY (2007)
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
Dominique Verhelle et al.
CANCER RESEARCH (2007)
The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo
Shabnam Shalapour et al.
CLINICAL CANCER RESEARCH (2006)
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignancies
R. A. Sharma et al.
EUROPEAN JOURNAL OF CANCER (2006)
Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells
J Komorowski et al.
LIFE SCIENCES (2006)
Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines
YP Gu et al.
EXPERIMENTAL CELL RESEARCH (2006)
Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
JB Bartlett et al.
BRITISH JOURNAL OF CANCER (2005)
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
K Dredge et al.
MICROVASCULAR RESEARCH (2005)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
JB Bartlett et al.
NATURE REVIEWS CANCER (2004)
Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905)
JP Dales et al.
BRITISH JOURNAL OF CANCER (2004)
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma
S Kumar et al.
LEUKEMIA (2004)
Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer
RS Saad et al.
MODERN PATHOLOGY (2004)
Thalidomide-derived immunomodulatory drugs as therapeutic agents
C Galustian et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2004)
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
S Chan
BRITISH JOURNAL OF CANCER (2004)
s-Thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line
WM Liu et al.
HEMATOLOGY JOURNAL (2004)
Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro
PAJ Haslett et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Role of MAP kinase in tumor progression and invasion
KB Reddy et al.
CANCER AND METASTASIS REVIEWS (2003)
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
K Dredge et al.
BRITISH JOURNAL OF CANCER (2002)
MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis
S Hiratsuka et al.
CANCER CELL (2002)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
N Mitsiades et al.
BLOOD (2002)
The importance of drug scheduling and recovery phases in determining drug activity: improving etoposide efficacy in BCR-ABL-positive CML cells
WM Liu et al.
EUROPEAN JOURNAL OF CANCER (2002)
Thalidomide: A novel template for anticancer drugs
D Stirling
SEMINARS IN ONCOLOGY (2001)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
Structure and function of VEGF/VEGF-receptor system involved in angiogenesis
M Shibuya
CELL STRUCTURE AND FUNCTION (2001)
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
G Bergers et al.
NATURE CELL BIOLOGY (2000)
Vascular-specific growth factors and blood vessel formation
GD Yancopoulos et al.
NATURE (2000)
Share Paper
